Affiliations: [a] Department of Clinical Pathology, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia | [b] Hasanuddin University Hospital, Makassar, Indonesia | [c] Dr. Wahidin Sudirohusodo Hospital, Makassar, Indonesia | [d] Lamadukkelleng Hospital, Sengkang, South Sulawesi, Indonesia | [e] PKU Muhammadiyah Hospital, Gombong Kebumen, Central Java, Indonesia | [f] Division of Oncology, Department of Surgery, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia
Correspondence:
[*]
Corresponding author: Liong Boy Kurniawan, Department of Clinical Pathology, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia. E-mail: [email protected]
Abstract: OBJECTIVES:Breast cancer is the most prevalent carcinoma found in Indonesian women, and its incidence remains high worldwide. Lipocalin 2 has been linked with the progression of breast cancer. Matrix metalloproteinase 9 (MMP9) is an enzyme that has an important role in angiogenesis. We investigated the relationship between lipocalin 2 and MMP9 and the ability of lipocalin 2 for predicting MMP9 levels in female patients with breast cancer. METHOD:A total of 55 female patients with breast cancer were enrolled in this cross-sectional study. Lipocalin 2 and MMP9 were measured by enzyme-linked immunosorbent assay. RESULTS:Lipocalin 2 was significantly correlated with MMP9 levels (r = 0.756, p < 0.001). Lipocalin 2 levels could describe the MMP9 levels (𝛽 = 0.76, p < 0.001, R2 = 56.9%). CONCLUSION:Higher lipocalin 2 levels in female patients with breast cancer indicate higher MMP9 levels. Lipocalin 2 can be used to predict MMP9 levels.
Keywords: Lipocalin 2, MMP9, breast cancer, female
DOI: 10.3233/BD-219017
Journal: Breast Disease, vol. 40, no. s1, pp. S115-S117, 2021
